Hepatitis C Virus: No Longer a Barrier to Oncology Care

Sobia N. Laique, Hugo E. Vargas

Research output: Contribution to journalReview articlepeer-review


Historically, hepatitis C virus infection has posed a barrier to cancer therapies and enrollment in clinical trials for oncology patients. Oral direct acting antivirals now allow most patients, previously considered difficult to treat to be effectively (>95% sustained virologic response) and safely cured.

Original languageEnglish (US)
Pages (from-to)207-208
Number of pages2
JournalAmerican Journal of Gastroenterology
Issue number2
StatePublished - Feb 1 2019

ASJC Scopus subject areas

  • Hepatology
  • Gastroenterology


Dive into the research topics of 'Hepatitis C Virus: No Longer a Barrier to Oncology Care'. Together they form a unique fingerprint.

Cite this